Business News • PR NewsWire • Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®

EAST HANOVER, N.J., June 4, 2016 /PRNewswire/ -- Novartis today announced at the 52nd American Society of Clinical Oncology (ASCO) Annual Meeting, the first results from the Tasigna (nilotinib) Treatment-free Remission (TFR) clinical trial program. These studies evaluated the...

View More : http://www.prnewswire.com/news-releases/novartis-data-show-more-than-50-percent-of-eligible-ph-cml-patients-maintain-tre...

Releted News by prnewswire

PR Pressure Conference: The PRessure Is On

Sepsis Alliance Mourns Loss of Boxing Legend Muhammad Ali to Sepsis at Age 74

BERG Announces Clinical Trial Data Presentations Of BPM 31510 In Advanced Solid Tumors And BPM 31543 For Prevention Of Chemotherapy-Induced Alopecia At American Society of Clinical Oncology Annual Meeting

Early-Phase Immuno-Oncology Studies of Lilly's ALIMTA® (pemetrexed) and CYRAMZA® (ramucirumab) with Merck's KEYTRUDA® (pembrolizumab) Show Encouraging Results in Non-Small Cell Lung Cancer